UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy

Size: px
Start display at page:

Download "UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy"

Transcription

1 A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts for this study at the Hospital of the University of Pennsylvania [HUP] are: Principal Investigator: Pablo Tebas, MD (215) Coordinator: Joseph Quinn, RN (215) Study Nurses: Kathryn Maffei, RN (215) Aleshia Thomas, RN (215) Wayne Wagner, RN (215) Carol DiGiorgio, RN (215) Hour Emergency Number (215) Ask for the Immunodeficiency Program Doctor on call Introduction: You are being asked to take part in this research study because you are infected with human immunodeficiency virus (HIV), the virus that causes AIDS, and are about to start anti-hiv drugs as part of an ACTG or non-actg antiretroviral therapy (ART) study or as standard of care. This study is sponsored by the National Institutes of Health (NIH)/ AIDS Clinical Trials Group (ACTG). The doctor in charge of this study at this site is Dr. Pablo Tebas. Before you decide if you want to be a part of this study, we want you to know about the study. This is a consent form. It gives you information about this study. The study staff will talk with you about this information. You are free to ask questions about this study at any time. If you agree to take part in this study, you will be asked to sign this consent form. You will get a copy to keep. Why Is This Study Being Done? The purpose of this study is to evaluate the presence of human papillamovirus (HPV) after anti-hiv drug initiation. We do not know if you have been infected with HPV, but will monitor your saliva for the presence of HPV and will examine your mouth for oral warts over the course of the study after you start taking the anti-hiv drugs as part of an ACTG or non-actg ART study or as standard of care. What Do I Have To Do If I Am In This Study? Screening If you would like to take part in this study and plan to enroll in an ACTG or a non-actg ART study, the screening evaluations to determine eligibility and pre-entry into A5272 can occur at the same time during the screening or pre-entry visit. If it is not possible to have the evaluations at the same visit, some of the evaluations may occur between the screening and entry visits. If you are not coenrolling in an ART study, the A5272 screening/pre-entry visit must occur on a separate day before the entry visit and within 30 days before ART is started. You should not eat, chew gum, mints or candy, brush/floss teeth, or smoke for 90 minutes before the saliva/throat wash collections. The visit for A5272 will take about minutes and will include: A throat wash collection by rinsing with a salt water solution for one minute and spitting the contents in a tube. Some throat wash will be stored for future HPV testing. Page 1 of 11

2 A saliva collection by spitting in a tube for 5-10 minutes to obtain 5 ml (one teaspoon) of saliva. Some saliva will be stored for future HPV testing. About 40 ml (8 teaspoons) of your blood will be collected and stored for future studies to look at your body s ability to fight HPV infection. If you are not coenrolling in an ACTG study, at this visit you will also have the following: Measurement of your HIV viral load (how much HIV is in your blood), and some routine blood tests for safety. You will be asked questions about your medical and medication history. Results of routine blood tests and CD4+ cell counts (cells that fight infections) and viral load (measure of HIV in the blood) evaluations will be given to you as soon as they are available Entry If you are eligible for this study and are coenrolling in an ACTG or non-actg ART study, entry evaluations should occur on the same day of the coenrolled study entry visit when possible, before study medication or ART is started. The entry visit for this study should last about 30 minutes and will include: Oral examination. Throat wash and saliva collection. Completion of a behavioral questionnaire. If you are not coenrolling in any ART study, the entry visit must occur on a separate day after the screening/pre-entry visit but before ART is started. ART must be started within 1 week of the A5272 study entry visit. This visit will take about 40 minutes and include all entry evaluations listed above. If you are not enrolling in an ACTG ART study, at this visit you will also have the following done at this visit: Blood drawn for routine safety tests, HIV viral load, and CD4+ and CD8+ cell counts. Any findings from the oral examination (e.g., presence of oral warts or other oral soft tissue abnormality) will be reported to you with a referral for follow-up care. All other test results (e.g., oral HPV DNA shedding) will be performed for research purposes only and will not be reported to you, since the clinical meaning of oral HPV shedding is not yet known. Post-Entry Evaluations You will have a study visit sometime between weeks after the entry visit in addition to weeks 24 and 48. These visits should last about 1 hour or less, and most visits will include the following: Oral examination. Throat wash and saliva collection. At the 24-week visit, about 40 ml (8 teaspoons) of your blood will be collected and stored for future studies to look at your body s ability to fight HPV infection. Completion of a behavioral questionnaire at weeks 24 and 48 only. Note: If you are coenrolling in an ACTG ART study, CD4+ cell count and HIV viral load are collected as part of these studies. The results will be obtained from the study teams after the ART study s Page 2 of 9

3 completion. If you are starting ART as part of routine clinical care or a non-actg ART study, CD4+ cell count and HIV viral load will be obtained at these visits listed above, as well as at week 4. Premature Discontinuation Evaluation If you are coenrolled in an ART study and prematurely discontinue from that study BEFORE week 24, you will be asked to return to the clinic to have the week 24 evaluations performed before being taken off study A5272. These evaluations will take about 40 minutes and include: Oral examination Throat wash Whole saliva collection Blood will be collected and stored for future tests Completion of a behavioral questionnaire Blood for safety test will be collected in participants who are enrolled in a non-actg ART study. If you discontinue AFTER week 24, you will have the following evaluations which should take about 40 minutes: Current medications/changes Oral Examination Blood collected for CD4 + cell count Completion of a behavioral questionnaire If you are a standard clinic care participant and discontinue this study, you will be asked to return to the clinic for a premature discontinuation evaluation. This evaluation will take about 40 minutes and will include evaluations as stated above and be based upon whether you discontinue before week 24 or after week 24. Note: If you are coenrolled in an ART study and discontinue or change to non-study treatment but remain on study for follow-up, you will have the option to remain enrolled in A5272. However, if you discontinue the study completely, you will be withdrawn from A5272. Other If you agree, any remaining blood, saliva, and throat wash (that was not used for study-related testing) will be stored with usual protectors of identity and may be used for future ACTG-approved HIV-related research. You may participate in this study even if you do not agree to have any remaining blood, saliva, and throat wash stored. These samples may be held for an indefinite length of time. We cannot ensure that you will be told the results of the research done on these samples. YES, I agree to have any remaining blood, saliva, and throat wash samples stored for future ACTG-approved research. NO, I DO NOT agree to have any remaining blood, saliva, and throat wash samples stored for future ACTG-approved research. Page 3 of 9

4 You can withdraw your consent to having your samples stored for future testing at any time. To withdraw your consent, please contact the study staff at your site. How Many People Will Take Part in This Study? About 500 people from U.S. sites will take part in this study. About people are expected to participate at the University of Pennsylvania. How Long Will I Be In This Study? You will be in this study for about 48 weeks. Why Would The Doctor Take Me Off This Study Early? The study doctor may need to take you off the study early without your permission if: The study is cancelled by the ACTG, the National Institutes of Health (NIH), Office for Human Research Protection (OHRP), or the University of Pennsylvania s Institutional Review Board (IRB). (An IRB is a committee that watches over the safety and rights of research participants.) You are not able to attend the study visits as required by the study. S/he thinks the study is no longer in your best interest. What Are The Risks Of The Study? Risk associated with having your blood drawn include: Discomfort associated with the needle piercing your skin Dizziness/feeling lightheaded, and/or fainting Bleeding or bruising at the spot where the needle enters your body Infection at site of puncture Risks associated with an examination of the mouth include: Discomfort Minor gagging Are There Risks Related To Pregnancy? There are no risks to unborn babies. Are There Benefits to Taking Part in This Study? If you take part in this study, there may be a direct benefit to you, but no guarantee can be made. It is also possible that you may receive no benefit from being in this study. Information learned from this study may help others who have HIV. What About Confidentiality? We will do everything we can to protect your privacy. In addition to the efforts of the study staff to help keep your personal information private, we have obtained a Certificate of Confidentiality from the U.S. Federal Government. This certificate means that researchers cannot be forced to tell people who are not connected with this study, such as the court system, about your participation. Also, any publication of this study will not use your name or identify you personally. Page 4 of 9

5 People who may review your records include the ACTG, Office for Human Research Protections (OHRP), University of Pennsylvania IRB, OHRP, National Institutes of Health (NIH), study staff, and study monitors. Having a Certificate of Confidentiality does not prevent you from releasing information about yourself and your participation in the study. Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse and/or neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities. HIPAA AUTHORIZATION The authorization part of the consent gives more detailed information about how your personal health information may be used and disclosed by the University of Pennsylvania Health System (UPHS), the School of Medicine and the individual Principal Investigator, subject to University of Pennsylvania procedures. What personal health information is collected and used in this study and might also be disclosed? The following personal health information will be collected, used for research, and may be disclosed during your involvement with this research study: Name, address, telephone number, date of birth Personal and family medical history Current and past medications or therapies Information from questionnaires administered in the study Results of tests and procedures you will undergo during this research study Why is your personal contact and health information being used? Your personal contact information is important for the research team to contact you during the study. Your personal health information and results of tests and procedures are being collected as part of this research study. In some situations, your personal health information might be used to help guide your medical treatment. Which of our personnel may use or disclose your personal health information? The following individuals may use or disclose your personal health information for this research study: The Principal Investigator and the Investigator s study team Authorized members of the workforce of the UPHS and the School of Medicine, and University of Pennsylvania support offices, who may need to access your information in the performance of their duties (for example: for research oversight and monitoring, to provide treatment, to manage accounting or billing matters, etc.). Who, outside of UPHS and the School of Medicine, might receive your personal health information? As part of the study, the Principal Investigator, the study team and others listed above, may disclose your personal health information, including the results of the research study tests and procedures. This information may be disclosed to those listed below: Individuals or organizations responsible for administering the study: - AACTG Data Coordinating Center, Frontier Science Technology Research Foundation (FSTRF): Data for this study will be recorded on case report forms, keyed into a central database and Page 5 of 9

6 electronically submitted to the Data Coordinating Center. The data will be cleaned and stored at this facility until it is ready to be analyzed. - Statistical Data Analysis Center (SDAC): Approved data will be downloaded from FSTRF to the statistical data center for the AACTG at the Harvard School of Public Health. Specific study reports will be periodically provided to the study team and data safety review board to monitor if the trial is safe. - Contract Research Organization (PPD, Inc): Monitors from PPD will visit the AACTG on a quarterly basis to review data and correct mistakes before the data are sent to SDAC for analysis. - Government Agencies: Data from this study will be made available to the Food and Drug Administration and to the National Institutes of Health/Division of AIDS (DAIDS)/National Institute for Allergy and Infectious Disease (NIAID), for them to evaluate the safety and efficacy of the treatments being used in this study. Regulatory and safety oversight organizations The Food and Drug Administration The Office of Human Research Protections The Study Monitoring Committee Once your personal health information is disclosed to others outside of UPHS or the School of Medicine, it may no longer be covered by federal privacy protection regulations. Data are reported to the sponsor on Case Report Forms that identify you by your unique study number and not your name, date of birth or medical record number. Information regarding your health, such as side effects of the study vaccine you experience will be reported only by code number. All samples collected for analysis will be labeled with your study number, visit number and date of your visit. The Principal Investigator or study staff will inform you if there are any additions to the list above during your active participation in the trial. Any additions will be subject to University of Pennsylvania procedures developed to protect your privacy. How long may UPHS and the School of Medicine be able to use or disclose your personal health information? Your authorization for use of your personal health information for this specific study does not expire. Your information may be held in a research repository (database). However, UPHS and the School of Medicine may not re-use or re-disclose information collected in this study for a purpose other than this study unless: You have given written authorization to do so The University of Pennsylvania s Institutional Review Board grants permission after ensuring that appropriate privacy safeguards are in place As permitted by law Will you be able to access your records? During your participation in this study, you might not be able to access some or all of your medical records. For example, access to portions of your medical records may be denied in studies where Page 6 of 9

7 your knowledge of study results included in such records could affect the reliability of the study. You will have access to your medical record information when the study is over or earlier, if possible. The Principal Investigator is not required to release research information to you that is not part of your medical record. Can you change your mind? Yes, at any time you may withdraw your approval to allow the use and disclosure of your personal health information as described here. You must do so in writing to the Principal Investigator at the address on the first page. Even if you withdraw your permission, your personal health information that was collected before we received your written request may still be used and disclosed, as necessary for the study. If you withdraw your permission to use your personal health information, you will also be withdrawn from the research study. If you withdraw your permission to use any blood or tissue obtained for the study, the Principal Investigator will ensure that these specimens are destroyed or will ensure that any information that could identify you is removed from these specimens. You will be given a copy of this Research Subject HIPAA Authorization describing your confidentiality and privacy rights for this study. You will also be given the UPHS and School of Medicine s Notice of Privacy Practices that contains more information about the privacy of your personal health information. What Are the Costs To Me? Taking part in this study may lead to added costs to you and your insurance company if you are diagnosed with a condition that would require referral for treatment. No treatment of any oral diseases will be performed as part of, or paid by this study, but you will be referred to the appropriate specialist should you require any treatment. In some cases, it is possible that your insurance company will not pay for these costs because you are taking part in a research study. Will I Receive Any Payment? You will be compensated $25 for each of the study required visits (screening, entry, weeks 12-18, 24, and 48) for a maximum of $125 compensation for this study. There is no other form of compensation available such as reimbursements for parking, tokens or child care available. Please note that if you receive more than $ compensation in one year for participation in research studies at the University of Pennsylvania, you must provide a Individual Tax Identification number or Social Security Number for tax purposes. What Happens If I Am Injured? If you have a medical emergency during the study you may contact the Principal Investigator or Emergency contact listed on page one of this form. You may also contact your own doctor, or seek treatment outside of the University of Pennsylvania. Be sure to tell the doctor or his/her staff that you are in a research study being conducted at the University of Pennsylvania. Ask them to call the telephone numbers on the first page of this consent form for further instructions or information about your care. Page 7 of 9

8 In the event of any physical injury resulting from research procedures, medical treatment will be provided without cost to you. There is no program for compensation either through the University of Pennsylvania or the National Institutes of Health. If you have an illness or injury during this research trial that is not directly related to your participation in this study, you and/or your insurance will be responsible for the cost of the medical care of that illness or injury. You do not give up your legal rights by signing this form. What Are My Rights As a Research Subject? Taking part in this study is completely voluntary. You may choose not to take part in this study or leave this study at any time. Your healthcare provider will treat you the same no matter what you decide. We will tell you about new information from this or other studies that may affect your health, welfare, or willingness to stay in this study. If you want the results of the study, let the study staff know. What Do I Do If I Have Questions Or Problems? For questions about this study or a research-related injury, contact: Pablo Tebas, MD ( ) Clinical Trials Unit ( ) For questions about your rights as a research subject, contact: Director of Regulatory Affairs at the University of Pennsylvania by phoning (215) CONSENT When you sign this form, you are agreeing to take part in this research study. This means that you have read the consent form, your questions have been answered, and you have decided to volunteer. Your signature also means that you are permitting the University of Pennsylvania Health System and the School of Medicine to use your personal health information collected about you for research purposes within our institution. You are also allowing the University of Pennsylvania Health System and the School of Medicine to disclose that personal health information to outside organizations or people involved with the operations of this study. A copy of this consent form will be given to you. You will also be given the University of Pennsylvania Health System and School of Medicine s Notice of Privacy Practices that contains more information about the privacy of your health information. Name of Subject (Please Print) Signature of Subject Date Name of Person Obtaining Signature Date Consent (Please Print) Page 8 of 9

9 For subjects unable to give authorization, the authorization is given by the following authorized subject representative: Authorized subject Authorized subject Date representative [print] representative Signature Provide a brief description of above person authority to serve as the subject s authorized representative. Page 9 of 9

IRB Approval From: 3/8/2010 To: 10/28/2010

IRB Approval From: 3/8/2010 To: 10/28/2010 UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 (Version 3.0, 16 FEB 2010) IRB Approval From:

More information

IRB Approved: 09-Jan-2015 To: 08-Jan-2016

IRB Approved: 09-Jan-2015 To: 08-Jan-2016 Developing Assays to Evaluate Immunologic Response to HIV and HIV Vaccines CONSENT FORM/HIPAA AUTHORIZATION FOR VENIPUNCTURE Investigators: Pablo Tebas, MD Phone Number: (215) 349-8092 Study Staff: Joseph

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM White Blood Cell Collection by Leukapheresis in HIV-infected Individuals On Chemotherapy and Controls Not on Chemotherapy: A Study of HIV Reservoir Eradication CONSENT TO PARTICIPATE IN A RESEARCH STUDY

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Gilead Sciences, Inc. GS-US-337-0115, 25-NOV-2013 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects

More information

IRB Approval From 6/9/15 to 2/15/16

IRB Approval From 6/9/15 to 2/15/16 CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5332 FINAL Version 2.0, dated 12/19/14 Randomized Trial to Prevent Vascular Events in HIV (The REPRIEVE

More information

IRB Approval from 3/29/16 to 2/14/17

IRB Approval from 3/29/16 to 2/14/17 CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5350, Version 1.0, 01/5/16: Safety, Tolerability and Effects of the Probiotic Visbiome Extra Strength

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol No. VRX496-USA-11-001-LTFU: Long-term Follow-up

More information

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5332 FINAL Version 3.0, dated 1/28/16; Letter of Amendment 1, 8/17/16; Letter of Amendment #2, 4/14/17

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM IRC 002, Version 5.0, 20 AUG 2012: A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-influenza A Immune Plasma for the Treatment of Influenza

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM IRC 004, Version 5, July 31, 2013 A Randomized Double-Blind Study Comparing Oseltamivir versus Placebo for the Treatment of Influenza in Low Risk Adults CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A Pilot Study for Collection of Anti-Zika Immune Plasma

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A Pilot Study for Collection of Anti-Zika Immune Plasma A Pilot Study for Collection of Anti-Zika Immune Plasma CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts for this study at the Hospital of the University

More information

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM Protocol Title: Principal Investigator: 24 hr. Emergency Contact: Evaluating the HIV-1 Reservoir: BEAT HIV Delaney

More information

University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION

University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: Evaluating the impact of cocaine use and HIV infection in arterial wall inflammation

More information

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5326 FINAL Version 2.0, dated 3/26/14 Safety, Pharmacokinetics and Immunotherapeutic Activity of an

More information

VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION

VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION Study Title: Cytokine Production and Lymphoproliferation With and Without Co-inhibitory Signaling Blockade: An Assessment of Functional

More information

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5341s, Version 1.0, 08/11/15: Size and Decay of HIV-1 Reservoirs in Tissues and Cerebrospinal Fluid

More information

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Study Title: Assessment of Biochemical Pathways and Biomarker Discovery in Autism Spectrum Disorder This is a research

More information

Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH

Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH Project Title: Genetics of Prostate Cancer Principal Investigator or Faculty Advisor: William J. Catalona, M.D.

More information

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: Principal Investigator: Lead Study Nurse: Research Team: 24 hr. Emergency Contact: A5329 version2.0,

More information

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Epileptic Encephalopathies: Clinical and Genetic Predictors of Outcomes and Therapeutic Insights This is a research study.

More information

The Johns Hopkins Bloomberg School of Public Health

The Johns Hopkins Bloomberg School of Public Health The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:

More information

Vanderbilt University Institutional Review Board Informed Consent Document for Research. Name of participant: Age:

Vanderbilt University Institutional Review Board Informed Consent Document for Research. Name of participant: Age: This informed consent applies to: Adults Name of participant: Age: The following is given to you to tell you about this research study. Please read this form with care and ask any questions you may have

More information

Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus

Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus Page 1 of 8 Informed Consent for Participation in a Research Study Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus Investigator Contact Information: Principal Investigator:

More information

About this consent form. Why is this research study being done? Partners HealthCare System Research Consent Form

About this consent form. Why is this research study being done? Partners HealthCare System Research Consent Form Protocol Title: Gene Sequence Variants in Fibroid Biology Principal Investigator: Cynthia C. Morton, Ph.D. Site Principal Investigator: Cynthia C. Morton, Ph.D. Description of About this consent form Please

More information

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH CC#:125519: Radiologically Guided Biopsies Of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms Of Resistance

More information

You are the parent or guardian granting permission for a child in this study.

You are the parent or guardian granting permission for a child in this study. Please check one of the following: You are an adult participant in this study. You are the parent or guardian granting permission for a child in this study. Print child s name here: The following information

More information

About this consent form

About this consent form Protocol Title: Development of the smoking cessation app Smiling instead of Smoking Principal Investigator: Bettina B. Hoeppner, Ph.D. Site Principal Investigator: n/a Description of Subject Population:

More information

3/6/2017-6/15/2017 Permission to Take Part in a Human Research Study Page 1 of 6

3/6/2017-6/15/2017 Permission to Take Part in a Human Research Study Page 1 of 6 Permission to Take Part in a Human Research Study Page 1 of 6 University at Buffalo Institutional Review Board (UBIRB) Office of Research Compliance Clinical and Translational Research Center Room 5018

More information

We are inviting you to participate in a research study/project that has two components.

We are inviting you to participate in a research study/project that has two components. Dear TEACCH Client: One of the missions of the TEACCH Autism Program is to support research on the treatment and cause of autism and related disorders. Therefore, we are enclosing information on research

More information

DF/HCC Principal Research Doctor / Institution: Irene Ghobrial, MD / DFCI

DF/HCC Principal Research Doctor / Institution: Irene Ghobrial, MD / DFCI Protocol Title: Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome DF/HCC Principal Research Doctor / Institution: Irene

More information

We are inviting you to participate in a research study/project that has two components.

We are inviting you to participate in a research study/project that has two components. Dear TEACCH Client: One of the missions of the TEACCH Autism Program is to support research on the treatment and cause of autism and related disorders. Therefore, we are enclosing information on research

More information

INFORMATION AND CONSENT FORM

INFORMATION AND CONSENT FORM INFORMATION AND CONSENT FORM A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY OF SELF- ADMINISTERED AND NURSE-ADMINISTERED INTRADERMAL INFLUENZA VACCINE Investigators Dr. Shelly McNeil Queen

More information

Subject Name: Sponsor Consent Tmplt Date: Version 2 (17-Jul-2014) Unit Number:

Subject Name: Sponsor Consent Tmplt Date: Version 2 (17-Jul-2014) Unit Number: SCREENING CONSENT TO DETERMINE STUDY ELIGIBILITY AND OPTIONAL RESEARCH AUTHORIZATION TO DONATE ARCHIVED TISSUE SAMPLES FOR MOLECULAR CHARACTERIZATION OF TUMOR YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW

More information

CONSENT TO PARTICIPATE IN A RESEARCH STUDY. Why are you being invited to take part in a research study?

CONSENT TO PARTICIPATE IN A RESEARCH STUDY. Why are you being invited to take part in a research study? HRP-502 (6/1/2016) LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER in Shreveport Institutional Review Board (IRB) for the Protection of Human Research Subjects Remove all instructional text and red color-coding

More information

Northwestern University. Consent Form and HIPAA Authorization for Research

Northwestern University. Consent Form and HIPAA Authorization for Research Northwestern University Consent Form and HIPAA Authorization for Research PROTOCOL TITLE: Yoga Versus Resistance Training in Parkinson s Disease: A Randomized, Controlled Pilot Study of Feasibility & Efficacy

More information

Research Consent Form Newton-Wellesley Hospital 2014 Washington Street Newton, MA 02462

Research Consent Form Newton-Wellesley Hospital 2014 Washington Street Newton, MA 02462 Protocol Title: Principal Investigator: Description of Subject Population: Protocol Version: Consent Form Revision Date: ABOUT THIS CONSENT FORM STUDY CONTACTS

More information

Language for Consent Forms

Language for Consent Forms New York University University Committee on Activities Involving Human Subjects 665 Broadway, Suite 804, New York, NY 10012 VOICE: 212-998-4808 FAX: 212-995-4304 www.nyu.edu/ucaihs/ Language for Consent

More information

Safety Regulations and Procedures Occupational Health Bloodborne Pathogens Exposure Control Plan S80.10, updated, May Contains information for:

Safety Regulations and Procedures Occupational Health Bloodborne Pathogens Exposure Control Plan S80.10, updated, May Contains information for: APPENDIX A Safety Regulations and Procedures Occupational Health Bloodborne Pathogens Exposure Control Plan S80.10, updated, May 2018 BLOODBORNE PATHOGEN EXPOSURE INCIDENT PACKET Contains information for:

More information

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014 Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: The goal of Assisted Reproductive Technology (ART) is to help infertile couples to become pregnant. During treatment, some cellular

More information

CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES 20730 Impact of CCR5 Blockade in CONSENT VERSION 3.0 /October 2, 2017 PROTOCOL VERSION 3.0 /October 2, 2017 [NOTE: Site specific

More information

Consent and Authorization Document

Consent and Authorization Document Kalani Raphael, MD Page 1 of 14 Consent and Authorization Document BACKGROUND You are being asked to participate in this research study because you have chronic kidney disease, also called CKD, a condition

More information

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT FORM

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT FORM UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT FORM Protocol Title: Principal Investigator: Emergency Contact: AN OPEN LABEL TRIAL OF MECASERMIN FOR HIV ASSOCIATED METABOLIC DISEASE Roy Kim

More information

Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee Phone:

Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee Phone: Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee 37601 Phone: 423-975-2200 Dear Parent: The Washington County Health Department

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Gilead Sciences, Inc. GS-US-337-0115, 25-NOV-2013 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects

More information

NCI Community Oncology Research Program Kansas City (NCORP-KC)

NCI Community Oncology Research Program Kansas City (NCORP-KC) NCI Community Oncology Research Program Kansas City (NCORP-KC) Consent Form Study Title for Study Participants: Comparing Two Dose Levels of Bupropion Versus Placebo for Sexual Desire Official Study Title

More information

CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY. University of Pittsburgh

CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY. University of Pittsburgh University of Pittsburgh Physicians, Department Of Critical Care Medicine Scaife Hall, Sixth Floor 3550 Terrace Street Pittsburgh, PA 15261 T 412-647-3136 F 412-647-8060 CONSENT TO ACT AS A PARTICIPANT

More information

CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY

CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY INVESTIGATOR S NAME: PAMELA S. HINTON PH.D. PROJECT # 1095877 DATE OF PROJECT APPROVAL: SEPTEMBER 12, 2007 STUDY TITLE: EFFICACY OF PLYOMETRICS TO INCREASE

More information

Bloodborne Pathogens. Post-Exposure Incident Packet. An Informational Guide

Bloodborne Pathogens. Post-Exposure Incident Packet. An Informational Guide Bloodborne Pathogens Post-Exposure Incident Packet An Informational Guide Faribault Public Schools Bloodborne Pathogens Post-Exposure Incident Packet This packet has been developed as an informational

More information

UNIVERSITY HOSPITALS CASE MEDICAL CENTER CONSENT FOR INVESTIGATIONAL STUDIES (v )

UNIVERSITY HOSPITALS CASE MEDICAL CENTER CONSENT FOR INVESTIGATIONAL STUDIES (v ) UNIVERSITY HOSPITALS CASE MEDICAL CENTER CONSENT FOR INVESTIGATIONAL STUDIES (v. 11.2012) Project Title: The Impact of Achilles Tightness on Lower Etremity Injuries in Adolescent Athletes Principal Investigator:

More information

University of Maryland College Park

University of Maryland College Park Page 1 of 7 Project Title Purpose of the Study Procedures Contagious Phenotypes of Acute Respiratory Infection: Identification, Characterization, and Biomarkers (Prometheus@UMD, GotFlu? Study) This research

More information

You are the parent or guardian granting consent for a minor in this study.

You are the parent or guardian granting consent for a minor in this study. Please check one of the following: You are an adult subject in this study. You are the parent or guardian granting consent for a minor in this study. Print minor's name here: The following information

More information

INFORMATION AND CONSENT FORM For Adults Aged 18 and Older Additional Facility Sites

INFORMATION AND CONSENT FORM For Adults Aged 18 and Older Additional Facility Sites INFORMATION AND CONSENT FORM Program Title: Expanded Access IND Program to Provide Stamaril Vaccine to Persons in the United States for Vaccination Against Yellow Fever Program #: Sponsor: Sanofi Pasteur

More information

Donor Registration and Consent for HLA Typing

Donor Registration and Consent for HLA Typing Place NMDP Bar Code label here Jackie (left), donated to save the life of Paizley (right) Randy (left), donated to save the life of Luke (right) Tobias (left), donated to save the life of Betsy (right)

More information

SOUTHSIDE COMMUNITY ACUPUNCTURE, LLC. Financial Policies

SOUTHSIDE COMMUNITY ACUPUNCTURE, LLC. Financial Policies Disclosure of Information - Please Read the Following Carefully How to Prepare for Your First Visit : Plan on showing up a 15 minutes early to your first appointment and please wear, or bring with you

More information

INFORMATION BROCHURE - ALLOCATE

INFORMATION BROCHURE - ALLOCATE INFORMATION BROCHURE - ALLOCATE AustraLian Ovarian Cancer Assortment Trial Principal Investigator: Prof Michael Quinn, Royal Women s Hospital This Participant Information Sheet and Consent Form is 7 pages

More information

KAISER PERMANENTE OF COLORADO CONSENT TO PARTICIPATE IN A MEDICAL RESEARCH STUDY

KAISER PERMANENTE OF COLORADO CONSENT TO PARTICIPATE IN A MEDICAL RESEARCH STUDY KAISER PERMANENTE OF COLORADO CONSENT TO PARTICIPATE IN A MEDICAL RESEARCH STUDY STUDY TITLE: Strategies for Overcoming Depression Symptoms Study (SOAR) PRINCIPAL INVESTIGATOR: Arne Beck You are being

More information

Pro Active Physical Therapy & Sports Medicine

Pro Active Physical Therapy & Sports Medicine Pro Active Physical Therapy & Sports Medicine Consent and Statement of Financial Responsibility 1. CONSENT FOR TREATMENT: I consent to and authorize my physical therapist, occupational therapist and other

More information

HREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank.

HREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank. HREC Project Number: Research Project Title: Principal Researchers: HREC/17/RCHM/334 RCH HREC 37278A ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank. Associate Professor Justine

More information

RESEARCH CONSENT FORM

RESEARCH CONSENT FORM Use Plate or Print: DO NOT PLACE IN MEDICAL RECORD Protocol Title: Genetic studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs) and their associated anomalies Principal Investigator:

More information

THE KRONGRAD INSTITUTE Sep 25, 2008 WIRB RESEARCH SUBJECT INFORMATION AND CONSENT FORM

THE KRONGRAD INSTITUTE Sep 25, 2008 WIRB RESEARCH SUBJECT INFORMATION AND CONSENT FORM RESEARCH SUBJECT INFORMATION AND CONSENT FORM TITLE: LAPAROSCOPIC PROSTATECTOMY FOR CHRONIC PROSTATITISA Phase II Non-Randomized Clinical Trial PROTOCOL NO.: 1 Protocol #20081635 SPONSOR: INVESTIGATOR:

More information

A study about how parts of the brain work in people with Down syndrome

A study about how parts of the brain work in people with Down syndrome A study about how parts of the brain work in people with Down syndrome Our names are Carla Startin, Sarah Hamburg and Ros Hithersay. We are researchers working at University College London. We are carrying

More information

Research Ethics Board Research Consent Form Genetic Analysis

Research Ethics Board Research Consent Form Genetic Analysis Participant name: DOB: HSC #: Research Ethics Board Research Consent Form Genetic Analysis Title of Research Project: Molecular and Genomic Analysis of Autism Spectrum and Associated Neurodevelopmental

More information

OUTPATIENT SERVICES PSYCHOLOGICAL SERVICES CONTRACT

OUTPATIENT SERVICES PSYCHOLOGICAL SERVICES CONTRACT OUTPATIENT SERVICES PSYCHOLOGICAL SERVICES CONTRACT (This is a detailed document. Please feel free to read at your leisure and discuss with Dr. Gard in subsequent sessions. It is a document to review over

More information

Informed Consent to Participate in Research

Informed Consent to Participate in Research Informed Consent to Participate in Research Principal Investigator Contact Information (Insert contact information for PI at your site) Study Sponsor: The National Institutes of Health (NIH) is sponsoring

More information

General Dental Treatment Consent Form

General Dental Treatment Consent Form General Dental Treatment Consent Form I authorize dental treatment including necessary or advisable examination, radiographs (x-rays), diagnostic aids or local anesthesia. In general terms, dental treatment

More information

IMPORTANT HEALTH INFORMATION

IMPORTANT HEALTH INFORMATION IMPORTANT HEALTH INFORMATION SU-6523MI Page 1 of 8 Table of Contents Page What is an HIV test?..........................................1 Will the HIV test tell me if I have AIDS?............................1

More information

SUBJECT INFORMATION AND INFORMED CONSENT FORM AND AUTHORIZATION TO DISCLOSE HEALTH INFORMATION

SUBJECT INFORMATION AND INFORMED CONSENT FORM AND AUTHORIZATION TO DISCLOSE HEALTH INFORMATION Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 24 SUBJECT INFORMATION AND INFORMED CONSENT FORM AND AUTHORIZATION TO DISCLOSE HEALTH INFORMATION Sponsor / Study Title: Protocol Number:

More information

CONSENT TO PARTICIPATE IN A RESEARCH STUDY. TITLE: Amantadine to Stimulate Wakefulness Following Post-Anoxic Encephalopathy

CONSENT TO PARTICIPATE IN A RESEARCH STUDY. TITLE: Amantadine to Stimulate Wakefulness Following Post-Anoxic Encephalopathy School of Medicine Department of Emergency Medicine Iroquois Building, Suite 400A 3600 Forbes Avenue Pittsburgh, PA 15261 412-647-3078 CONSENT TO PARTICIPATE IN A RESEARCH STUDY TITLE: Amantadine to Stimulate

More information

PSYCHOLOGIST-PATIENT SERVICES

PSYCHOLOGIST-PATIENT SERVICES PSYCHOLOGIST-PATIENT SERVICES PSYCHOLOGICAL SERVICES Welcome to my practice. Because you will be putting a good deal of time and energy into therapy, you should choose a psychologist carefully. I strongly

More information

Carter Physiotherapy, PLLC Patient Contact Information

Carter Physiotherapy, PLLC Patient Contact Information Carter Physiotherapy, PLLC Patient Contact Information Patient Name Today s Date Address City State Zip DOB Age Gender Marital Status Cell Phone Home Phone Email Employer Occupation Parent/Guardian/Spouse

More information

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith CONSENT FORM The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith Queen Elizabeth Hospital Queen Elizabeth Hospital 60 Riverside Drive 60

More information

CONSENT TO GENETIC TESTING THROUGH A RESEARCH STUDY

CONSENT TO GENETIC TESTING THROUGH A RESEARCH STUDY CONSENT TO GENETIC TESTING THROUGH A RESEARCH STUDY Title Principal Investigator Genetic Counsellor Prevent Ovarian Cancer Program: Systematic identification of high-risk women for ovarian cancer prevention

More information

University of California, San Diego. Colesevelam versus placebo in the treatment of nonalcoholic steatohepatitis

University of California, San Diego. Colesevelam versus placebo in the treatment of nonalcoholic steatohepatitis University of California, San Diego 091491 6 Pages Colesevelam versus placebo in the treatment of nonalcoholic steatohepatitis Collection, Storage, and Use of Blood Samples for Current and Future Genetic

More information

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1 The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment

More information

Initial Clinical History and Physical Form

Initial Clinical History and Physical Form 601 E FM 544, Suite 400, Murphy, TX, 75094 TEL: 972-442-4700 Initial Clinical History and Physical Form Patient Information Name: Age: of Birth: / / Sex: Male / Female Marital Status: Single Married Divorced

More information

Cancer Studies at the National Institutes of Health Clinical Center: Questions and Answers. Key Points

Cancer Studies at the National Institutes of Health Clinical Center: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Cancer Studies at the

More information

INFORMED CONSENT FORM TO TAKE PART IN A RESEARCH STUDY

INFORMED CONSENT FORM TO TAKE PART IN A RESEARCH STUDY Page 1 of 12 **FOR CCI USE ONLY** Approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations: Administrator: Astrid Joseph (JG) Consent Approval Date: 8/14/15 Protocol Number:

More information

New Patient Information

New Patient Information Patient's Street Address: Home Phone: Cell Phone: of Birth: / / New Patient Information State: Name of Person Responsible for This Account: E-Mail Address: Zip Code: Work Phone: SSN: Do You Have Dental

More information

Effective Date: 9/14/06 NOTICE PRIVACY RULES FOR VALUEOPTIONS

Effective Date: 9/14/06 NOTICE PRIVACY RULES FOR VALUEOPTIONS Effective Date: 9/14/06 NOTICE PRIVACY RULES FOR VALUEOPTIONS This notice describes how medical information about you may be used and disclosed and how you can get access to this information. If you have

More information

UNIVERSITY OF CALIFORNIA, SAN DIEGO CONSENT TO ACT AS A RESEARCH SUBJECT

UNIVERSITY OF CALIFORNIA, SAN DIEGO CONSENT TO ACT AS A RESEARCH SUBJECT 15 pages UNIVERSITY OF CALIFORNIA, SAN DIEGO CONSENT TO ACT AS A RESEARCH SUBJECT ADULT CONSENT Protocol Title: (CPAP)-Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients with

More information

PATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN)

PATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN) XOLAIR Access Solutions is a free program for you from Genentech. We work to help you pay for your XOLAIR (omalizumab) for subcutaneous use. We can help in many different ways. We assist people who have

More information

Understanding Clinical Trials

Understanding Clinical Trials An excerpt from: Understanding Clinical Trials What is a clinical trial? Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research

More information

UPCOMING CHANGES TO THE FORMAT OF INFORMED CONSENT DOCUMENTS

UPCOMING CHANGES TO THE FORMAT OF INFORMED CONSENT DOCUMENTS UPCOMING CHANGES TO THE FORMAT OF INFORMED CONSENT DOCUMENTS The changes to regulations on human subjects research, set to begin in January 2018, have a new requirement about how informed consent documents

More information

Dr. Mark VanOtterloo DAOM - Licensed Acupuncturist

Dr. Mark VanOtterloo DAOM - Licensed Acupuncturist Please keep your healthcare practitioner aware of any changes to your personal information as soon as possible THANK YOU! Patient Info Printed Name: Address: DOB: / / Gender: Marital Status: S M D W Employer:

More information

JACKSONVILLE SPEECH & HEARING CENTER PATIENT INFORMATION FORM PEDIATRIC (CHILD) - AUDIOLOGY Please Print

JACKSONVILLE SPEECH & HEARING CENTER PATIENT INFORMATION FORM PEDIATRIC (CHILD) - AUDIOLOGY Please Print JACKSONVILLE SPEECH & HEARING CENTER PATIENT INFORMATION FORM PEDIATRIC (CHILD) - AUDIOLOGY Please Print Referring Physician: Child s (Patient) Name: LAST FIRST MIDDLE Gender: Male Female Date of Birth:

More information

A study of Standard and New Antiepileptic Drugs SANAD-II

A study of Standard and New Antiepileptic Drugs SANAD-II The SANAD II project is funded by the NIHR Health Technology Assessment Programme. Hospital Logo Address NIHR code A study of Standard and New Antiepileptic Drugs SANAD-II ADULT INFORMATION SHEET www.sanad2.org.uk

More information

For Parents and Students: Minor Donor Permit and Information About Donating Blood

For Parents and Students: Minor Donor Permit and Information About Donating Blood DIN NUMBER 102 Chestnut Ridge Road, Montvale NJ 07645 DID For Parents and Students: Minor Donor Permit and Information About Donating Blood Every day people like you need blood: students, teachers, family,

More information

SUBJECT INFORMATION AND INFORMED CONSENT FORM AND AUTHORIZATION TO DISCLOSE HEALTH INFORMATION STUDY EXTENSION

SUBJECT INFORMATION AND INFORMED CONSENT FORM AND AUTHORIZATION TO DISCLOSE HEALTH INFORMATION STUDY EXTENSION Page 1 of 20 SUBJECT INFORMATION AND INFORMED CONSENT FORM AND AUTHORIZATION TO DISCLOSE HEALTH INFORMATION STUDY EXTENSION Study Name: Protocol No: Study Sponsor: Study Doctor: A Phase III Multicenter,Double-Blind,Randomized,Active

More information

National Emphysema Treatment Trial (NETT) Consent for Randomization to Treatment

National Emphysema Treatment Trial (NETT) Consent for Randomization to Treatment National Emphysema Treatment Trial (NETT) Consent for Randomization to Treatment Instructions: This consent statement is to be signed and dated by the patient in the presence of a certified study staff

More information

Human Subject Institutional Review Board Proposal Form

Human Subject Institutional Review Board Proposal Form FOR IRB USE ONLY Protocol Number: IRB- Human Subject Institutional Review Board Proposal Form Activity Title: PRINCIPAL INVESTIGATOR ASSURANCE I agree to use procedures with respect to safeguarding human

More information

Adult Patient Information and Consent Form

Adult Patient Information and Consent Form The ROAM Trial Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

More information

FLIPS FreeStyle Libre in Pregnancy Study

FLIPS FreeStyle Libre in Pregnancy Study FLIPS FreeStyle Libre in Pregnancy Study Evaluation of the Accuracy of the FreeStyle Libre Flash Glucose Monitoring System Use in Pregnancy Label Extension Study (CE) Section 1: PARTICIPANT INFORMATION

More information

New patients approved for the Novo Nordisk PAP may only be eligible for insulin vials. For a full list of available products, please visit:

New patients approved for the Novo Nordisk PAP may only be eligible for insulin vials. For a full list of available products, please visit: The Novo Nordisk Diabetes Patient Assistance Program (PAP) provides medication to qualifying applicants at no charge. If the applicant qualifies under the Novo Nordisk Diabetes PAP guidelines, a 120-day

More information

Quality of Life of HIV-infected Patients Study

Quality of Life of HIV-infected Patients Study Investigator Name: Quality of Life of HIV-infected Patients Study OptumInsight is seeking for additional investigators for a multicenter longitudinal observational study involving adult patients with HIV.

More information

Clinical Trials: Questions and Answers

Clinical Trials: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Clinical Trials: Questions

More information

Physical Evidence Chiropractic 7035 Beracasa Way, Suite 103 Boca Raton Florida, Phone# (561) Fax# (561)

Physical Evidence Chiropractic 7035 Beracasa Way, Suite 103 Boca Raton Florida, Phone# (561) Fax# (561) 7035 Beracasa Way, Suite 103 Boca Raton Florida, 33433 Phone# (561)674-1217 Fax# (561)361-4999 Date File # PERSONAL HISTORY Last Name First Name middle Address City State Zip Date of Birth Age Social Security

More information

Access Endodontics Marat Tselnik, DDS -PRACTICE LIMITED TO ENDODONTICS-

Access Endodontics Marat Tselnik, DDS -PRACTICE LIMITED TO ENDODONTICS- Access Endodontics Marat Tselnik, DDS -PRACTICE LIMITED TO ENDODONTICS- REFERRED BY: TODAY S DATE: PATIENT NAME HOME PHONE (LAST) (FIRST) (MIDDLE) E-MAIL CELL PHONE HOME ADDRESS (STREET) (CITY) (STATE)

More information

Elements of Informed Consent. Lu Pai, Ph.D. Associate Professor, Taipei Medical University IRB member, Tri-service General Hospital

Elements of Informed Consent. Lu Pai, Ph.D. Associate Professor, Taipei Medical University IRB member, Tri-service General Hospital Elements of Informed Consent Lu Pai, Ph.D. Associate Professor, Taipei Medical University IRB member, Tri-service General Hospital Informed Consent Informed consent is process of ensuring that subjects

More information

If you want to learn more about this study, you are welcome to read the full consent form and the patient handbook.

If you want to learn more about this study, you are welcome to read the full consent form and the patient handbook. What is this research study about? You are being asked to be in this study because you are at increased risk of getting type 1 diabetes. You have already been assigned to a treatment group and have completed

More information

NCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG Informed Consent Template for Cancer Treatment Trials (English Language)

NCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG Informed Consent Template for Cancer Treatment Trials (English Language) Page 1 of 15 NCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG 1112 Informed Consent Template for Cancer Treatment Trials (English Language) RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS

More information